Psychotropic dose equivalence in Japan

被引:382
作者
Inada, Toshiya [1 ]
Inagaki, Ataru [2 ,3 ]
机构
[1] Seiwa Hosp, Inst Neuropsychiat, Tokyo 1620851, Japan
[2] Aoyama Gakuin Univ, Sch Int Polit Econ & Commun, Tokyo, Japan
[3] Aoyama Gakuin Univ, Hlth Adm Ctr, Tokyo, Japan
关键词
antidepressant; antiparkinsonian drugs; antipsychotic; anxiolytic; dose equivalence; hypnotic; RESEARCH-TEAM PORT; TREATMENT RECOMMENDATIONS; EXTRAPYRAMIDAL SYMPTOMS; SCHIZOPHRENIA; DRUGS;
D O I
10.1111/pcn.12275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychotropic dose equivalence is an important concept when estimating the approximate psychotropic doses patients receive, and deciding on the approximate titration dose when switching from one psychotropic agent to another. It is also useful from a research viewpoint when defining and extracting specific subgroups of subjects. Unification of various agents into a single standard agent facilitates easier analytical comparisons. On the basis of differences in psychopharmacological prescription features, those of available psychotropic agents and their approved doses, and racial differences between Japan and other countries, psychotropic dose equivalency tables designed specifically for Japanese patients have been widely used in Japan since 1998. Here we introduce dose equivalency tables for: (i) antipsychotics; (ii) antiparkinsonian agents; (iii) antidepressants; and (iv) anxiolytics, sedatives and hypnotics available in Japan. Equivalent doses for the therapeutic effects of individual psychotropic compounds were determined principally on the basis of randomized controlled trials conducted in Japan and consensus among dose equivalency tables reported previously by psychopharmacological experts. As these tables are intended to merely suggest approximate standard values, physicians should use them with discretion. Updated information of psychotropic dose equivalence in Japan is available at . [Correction added on 8 July 2015, after first online publication: A link to the updated information has been added.]
引用
收藏
页码:440 / 447
页数:8
相关论文
共 46 条
[1]  
Akimoto T, 2005, RINSYO SEISHIN YAKUR, V8, P1199
[2]  
[Anonymous], 1998, PSYCHIAT B R COLL PS, DOI DOI 10.1192/PB.22.1.15
[3]  
[Anonymous], JPN J CLIN PSYCHOPHA
[4]   ANTIPARKINSONIAN DRUGS IN THE TREATMENT OF NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SYMPTOMS [J].
BEZCHLIBNYKBUTLER, KZ ;
REMINGTON, GJ .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1994, 39 (02) :74-84
[5]  
BINDER RL, 1987, AM J PSYCHIAT, V144, P1494
[6]   Inpatient antipsychotic drug use in 1998, 1993, and 1989 [J].
Centorrino, F ;
Eakin, M ;
Bahk, WM ;
Kelleher, JP ;
Goren, J ;
Salvatore, P ;
Egli, S ;
Baldessarini, RJ .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) :1932-1935
[7]   DOSE EQUIVALENCE OF ANTI-PSYCHOTIC DRUGS [J].
DAVIS, JM .
JOURNAL OF PSYCHIATRIC RESEARCH, 1974, 11 :65-69
[8]  
desLeon J, 1994, HOSP COMMUNITY PSYCH, V45, P606
[9]   Definition and epidemiology of treatment-resistant depression [J].
Fava, M ;
Davidson, KG .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1996, 19 (02) :179-&
[10]   Are the Cochrane group registers comprehensive? A case study of Japanese psychiatry trials [J].
Furukawa T.A. ;
Inada T. ;
Adams C.E. ;
McGuire H. ;
Inagaki A. ;
Nozaki S. .
BMC Medical Research Methodology, 2 (1) :1-3